Company Overview of Karus Therapeutics Limited
Karus Therapeutics Limited designs and develops cancer therapies. The company’s portfolio includes orally-active small molecule drugs, such as KA2237, a dual-selective inhibitor of PI3K isoforms, such as p110ß and p110d for treating hematological and solid tumors; and KA2507 (HDAC6) for PD-L1 expressing tumors. The company was incorporated in 2005 and is based in Oxfordshire, United Kingdom.
Oxfordshire, OX11 0SG
Founded in 2005
44 1235 829140
44 1235 420517
Key Executives for Karus Therapeutics Limited
Karus Therapeutics Limited Key Developments
Similar Private Companies By Industry
|Achilles Therapeutics Ltd.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Karus Therapeutics Limited, please visit www.karustherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.